Kailera Therapeutics, Inc. (KLRA)
Q2-CY2026Q1-CY2026Q4-CY2025Q3-CY2025Q2-CY2025Q1-CY2025Q4-CY2024Q3-CY2024Q2-CY2024Q1-CY2024Q4-CY2023Q3-CY2023Q2-CY2023Q1-CY2023Q4-CY2022Q3-CY2022Q2-CY2022Q1-CY2022Q4-CY2021Q3-CY2021Q2-CY2021Q1-CY2021Q4-CY2020Q3-CY2020Q2-CY2020Q1-CY2020Q4-CY2019Q3-CY2019Q2-CY2019Q1-CY2019Q4-CY2018Q3-CY2018Q2-CY2018Q1-CY2018Q4-CY2017Q3-CY2017Q2-CY2017Q1-CY2017Q4-CY2016Q3-CY2016Q2-CY2016Q1-CY2016Q4-CY2015Q3-CY2015Q2-CY2015Q1-CY2015Q4-CY2014Q3-CY2014Q2-CY2014
Balance Sheet Date2026-Mar-31
Fiscal PeriodQ1-FY2026
Total Assets624,756,000$692,294,000$
Total Current Assets530,315,000$557,537,000$
Cash and Cash Equivalents111,826,000$160,267,000$101,776,000$
Receivables
Other Current Assets360,000$1,234,000$
Assets Held for Sale in Short Term
Total Noncurrent Assets94,441,000$134,757,000$
Goodwill
Other Intangible Assets
Physical Assets1,854,000$1,955,000$
Other Noncurrent Assets5,591,000$2,721,000$
Assets Held for Sale in Long Term
Total Liabilities64,480,000$56,388,000$
Total Current Liabilities54,836,000$46,405,000$
Accounts Payable7,095,000$7,529,000$
Short Term Debt
Short Term Capital Lease Obligations1,027,000$1,040,000$
Other Current Liabilities722,000$916,000$
Total Noncurrent Liabilities9,644,000$9,983,000$
Long Term Debt
Long Term Capital Lease Obligations9,443,000$9,713,000$
Other Noncurrent Liabilities201,000$270,000$
Total Equity(432,088,000$)(356,458,000$)(235,238,000$)
Equity to Minority
Equity to Common Shareholders(432,088,000$)(356,458,000$)(235,238,000$)
Additional Paid-In Capital
Retained Earnings(447,533,000$)(368,668,000$)
Treasury Stock
Capital Lease Obligations10,470,000$10,600,000$